Cambridge Investment Research Advisors Inc. raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) by 197.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 248,139 shares of the biotechnology company’s stock after acquiring an additional 164,792 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Anavex Life Sciences were worth $2,129,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in AVXL. Northern Trust Corp lifted its stake in shares of Anavex Life Sciences by 1.6% in the fourth quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company’s stock worth $7,592,000 after acquiring an additional 10,938 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Anavex Life Sciences by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company’s stock worth $7,273,000 after purchasing an additional 11,239 shares during the last quarter. Invesco Ltd. lifted its position in shares of Anavex Life Sciences by 2,419.8% in the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company’s stock worth $6,606,000 after purchasing an additional 590,639 shares during the period. Pier Capital LLC bought a new stake in shares of Anavex Life Sciences in the 4th quarter valued at $4,746,000. Finally, Essential Planning LLC. bought a new stake in shares of Anavex Life Sciences in the 4th quarter valued at $4,437,000. Institutional investors and hedge funds own 31.55% of the company’s stock.
Anavex Life Sciences Stock Performance
Shares of AVXL stock opened at $9.33 on Wednesday. Anavex Life Sciences Corp. has a fifty-two week low of $4.00 and a fifty-two week high of $14.44. The stock has a 50 day simple moving average of $8.53 and a two-hundred day simple moving average of $9.10. The company has a market cap of $796.50 million, a P/E ratio of -16.96 and a beta of 0.71.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on AVXL. HC Wainwright reissued a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital reiterated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.
View Our Latest Stock Analysis on Anavex Life Sciences
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Stories
- Five stocks we like better than Anavex Life Sciences
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
- Canada Bond Market Holiday: How to Invest and Trade
- Breakout Alert: Disney Stock Hits Multi-Year High
- What is the Dow Jones Industrial Average (DJIA)?
- Forget IBM: Accenture’s AI Momentum Is Your Next Buy
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.